Hiroshi Inano, Yoshihito Morimoto, Kanata Kitagawa, Akito Shibuya, Kozue Nakagomi, Tomohiro Ota, Yuri Anzo, Rika Miyauchi, Aiko Shono, Kazuhiro Watanabe, Katsuya Otori
Existing antiemetic therapy against emetic-risk agents across malignancies 24 h post-dose in the acute period in CDDP-based regimens yields a satisfactory complete response (CR) rate of ≥ 90%. However, the control rate after 24 h in the delayed period is unsatisfactory. This study compared the efficacy of fosnetupitant (F-NTP), a neurokinin 1 receptor antagonist, with that of fosaprepitant (F-APR) and aprepitant (APR) in the treatment of patients with cancer at high emetic risk due to chemotherapy. In this retrospective case-control study involving patients receiving cisplatin-containing regimens and neurokinin 1 receptor antagonists, patients were divided into three groups based on prophylactic antiemetic therapy: F-NTP, F-APR, and APR...
February 28, 2024: Biological & Pharmaceutical Bulletin